Reuters news service reports that the United States Food and Drug
Administration (FDA) has told the maker of the flu drug Relenza to
strengthen warning labels on the drug after receiving reports of patient
hospitalization and possibly deaths that could be linked to it.
Last year, the British government ruled that Relenza should not be
reimbursed on the state-run National Health Service because there are
doubts about its benefits and high costs.
As a result of the FDA's findings, Glaxo has written to doctors warning
them that the drug may have contributed to breathing problems in
patients with respiratory problems as well as to a decline in respiratory
function in patients without a history of airway disease.
Glaxo hopes to offer new information to show that Relenza is valuable to
"older" flu sufferers.
We hope that would not be those older patients who suffer from a
decline in respiratory function without a history of airway disease.
In Touch
Vol. 4, No. 8 August 2000 ISSN 1525-416X
© 2000 In Touch P.O. Box 2353 Peachtree City, GA 30269